LEADER 04347nam 2200613 a 450 001 9910792593403321 005 20200520144314.0 010 $a1-282-58491-X 010 $a9786612584916 010 $a0-226-55179-2 024 7 $a10.7208/9780226551791 035 $a(CKB)2670000000019430 035 $a(EBL)534569 035 $a(OCoLC)635292171 035 $a(SSID)ssj0000422894 035 $a(PQKBManifestationID)11310896 035 $a(PQKBTitleCode)TC0000422894 035 $a(PQKBWorkID)10432559 035 $a(PQKB)10091588 035 $a(StDuBDS)EDZ0000115688 035 $a(MiAaPQ)EBC534569 035 $a(DE-B1597)524681 035 $a(DE-B1597)9780226551791 035 $a(Au-PeEL)EBL534569 035 $a(CaPaEBR)ebr10389542 035 $a(CaONFJC)MIL258491 035 $a(EXLCZ)992670000000019430 100 $a20020712d2003 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aMeasuring the gains from medical research$b[electronic resource] $ean economic approach /$fedited by Kevin M. Murphy and Robert H. Topel 210 $aChicago $cUniversity of Chicago Press$dc2003 215 $a1 online resource (270 p.) 300 $aDescription based upon print version of record. 311 $a0-226-55178-4 320 $aIncludes bibliographical references and indexes. 327 $aThe health of nations: the contribution of improved health to living standards / William D. Nordhaus -- The economic value of medical research / Kevin M. Murphy and Robert Topel -- Pharmaceutical innovation, mortality reduction, and economic growth / Frank R. Lichtenberg -- The return to biomedical research: treatment and behavioral effects / David M. Cutler and Srikanth Kadiyala -- Biomedical research and then some: the causes of technological change in heart attack treatment / Paul Heidenreich and Mark McClellan -- Can medical cost-effectiveness analysis identify the value of research? / David Meltzer. 330 $aIn 1998, health expenditures in the United States accounted for 12.9% of national income-the highest share of income devoted to health in the developed world. The United States also spends more on medical research than any other country-in 2000, the federal government dedicated $18.4 billion to it, compared with only $3.7 billion for the entire European Union. In this book, leading health economists ask whether we are getting our money's worth. From an economic perspective, they find, the answer is a resounding "yes": in fact, considering the extraordinary value of improvements to health, we may even be spending too little on medical research. The evidence these papers present and the conclusions they reach are both surprising and convincing: that growth in longevity since 1950 has been as valuable as growth in all other forms of consumption combined; that medical advances producing 10% reductions in mortality from cancer and heart disease alone would add roughly $10 trillion-a year's GDP-to the national wealth; or that the average new drug approved by the FDA yields benefits worth many times its cost of development. The papers in this book are packed with these and many other surprising revelations, their sophisticated analysis persuasively demonstrating the massive economic benefits we can gain from investments in medical research. For anyone concerned about the cost and the value of such research-from policy makers to health care professionals and economists-this will be a landmark book. 606 $aMedicine$xResearch$xCost effectiveness$vCongresses 610 $ahealth expenditure, national income, medical research, government, funding, longevity, innovation, technology, development, fda, prescription drugs, pharmaceuticals, gdp, heart disease, cancer, mortality, cost effectiveness, economics, politics, economy, nonfiction, medicine, healthcare, living standards, biomedical, growth, quality of life, illness. 615 0$aMedicine$xResearch$xCost effectiveness 676 $a362.1/068 701 $aMurphy$b Kevin M$0119818 701 $aTopel$b Robert H$0145544 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910792593403321 996 $aMeasuring the gains from medical research$93726747 997 $aUNINA